RBC Capital analyst Luca Issi maintained a Hold rating on Moderna (MRNA – Research Report) on January 13 and set a price target of $40.00. The company’s shares closed yesterday at $34.77.

Analyst Mani Foroohar of Leerink Partners maintained a Sell rating on Moderna (MRNA – Research Report), reducing the price target to $27.00. Discover outperforming stocks and invest smarter with ...

The company also delayed its break-even timeline from 2026 to 2028. View of Moderna company office entrance exterior with logo sign in Cambridge, Massachusetts, June 14, 2024. Shares fell 19 ...

Today, we will plunge into the realm of sportswear logos. The top 10 brands will be ranked according to how much they have affected this business. What comes to mind when you think about sportswear?

(Reuters) -Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines, sending its ...

Shares plunge more than 24% in early trading 2025 revenue forecast misses expectations, prior view CEO Bancel says to reduce 2025 cash costs by $1 bln Jan 13 (Reuters) - Moderna (MRNA.O), opens ...

Moderna cut its 2025 sales forecast by $1 billion today, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines, sending its shares down more ...

The NHL has some of the most historic and unique logos in the entire world of sports. With the Seattle Kraken now in the fold, we can rank 32 logos around the league. There are many great logos ...

Moderna's partnership with Merck in personalized cancer therapies and promising Phase III trials support a speculative 'Buy' for long-term investors with high-risk tolerance. Despite a tough 2024 ...

1 Day MRNA 10.10% DJIA 0.92% S&P 500 0.53% Health Care/Life Sciences -0.58% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...